Orchestra BioMed
OBIO
48 hedge funds and large institutions have $121M invested in Orchestra BioMed in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
0.24% more ownership
Funds ownership: 59.42% → 59.66% (+0.24%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $124M → $121M (-$2.95M)
4% less funds holding
Funds holding: 50 → 48 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$2.2M |
| 2 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$1.14M |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$987K |
| 4 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$976K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$790K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.45M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.19M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.02M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$912K |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$758K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MS
51
Maven Securities
St Helier,
Jersey
| – | -$912K | -91,715 | Closed |
|
|
52
Janus Henderson Group
London,
United Kingdom
| – | -$758K | -74,049 | Closed |
|
|
BCP
53
Berylson Capital Partners
Boston,
Massachusetts
| – | -$473K | -46,346 | Closed |
|
|
FIA
54
FNY Investment Advisers
New York
| – | -$51K | -5,000 | Closed |
|
OBIO Hedge Fund Activity: Q3 2021 in Review
48 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q3 2021, worth a combined $121M — down 2.4% from $124M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of OBIO and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 10 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $2.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.45M sold.
- 48 institutional investors held Orchestra BioMed (OBIO) as of Q3 2021, down from 50 in Q2 2021.
- Funds reported $121M of Orchestra BioMed stock for Q3 2021, down 2.4% quarter-over-quarter.
- 4 funds opened new Orchestra BioMed positions in Q3 2021 and 6 closed out, a net change of -2 holders.
- The largest Orchestra BioMed buyer in Q3 2021 was D.E. Shaw & Co, an estimated $2.2M added.
- The largest Orchestra BioMed seller in Q3 2021 was Cormorant Asset Management, an estimated $2.45M sold.
Based on aggregated 13F filings for Q3 2021.